Direct Antilymphoma Effects on Human Lymphoma Cells of Monotherapy and Combination Therapy with CD20 and HLA-DR Antibodies and 90Y-Labeled HLA-DR Antibodies
Open Access
- 1 October 2005
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 11 (19) , 7075s-7079s
- https://doi.org/10.1158/1078-0432.ccr-1004-0008
Abstract
Purpose: Fludarabine and cyclophosphamide is an effective combination but increases the risk of opportunistic infections due to depressed lymphocyte counts. In an attempt to preserve CD4 counts, we conducted a phase I, double-blind, placebo-controlled trial of recombinant interleukin-2 (IL-2) added to fludarabine and cyclophosphamide in patients with treatment-naive indolent lymphomas or chronic lymphocytic leukemia.Keywords
This publication has 13 references indexed in Scilit:
- Antilymphoma Effects of Anti-HLA-DR and CD20 Monoclonal Antibodies (Lym-1 and Rituximab) on Human Lymphoma CellsCancer Biotherapy & Radiopharmaceuticals, 2004
- Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistanceOncogene, 2003
- MHC class II isotype-specific signaling complex on human B cellsEuropean Journal of Immunology, 2002
- Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s LymphomaJournal of Clinical Oncology, 2002
- Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab)Seminars in Oncology, 2002
- Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-Refractory Low-Grade or Transformed Low-Grade B-Cell Non-Hodgkin’s LymphomasJournal of Clinical Oncology, 2001
- Re-Treatment of Relapsed Indolent B-Cell Lymphoma With RituximabInternational Journal of Hematology, 2001
- Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.Journal of Clinical Oncology, 1998
- Lymphoma-selective antibody Lym-1 recognizes a discontinuous epitope on the light chain of HLA-DR10Cancer Immunology, Immunotherapy, 1996
- Antitumor effects of L6, an IgG2a antibody that reacts with most human carcinomas.Proceedings of the National Academy of Sciences, 1986